Accessibility setting


Select language

Skip to secondary menu

Skip to content

Jehovah’s Witnesses


Hematology (Autoimmune Diseases and Conditions)

Immune (Idiopathic) Thrombocytopenic Purpura

Efficacy of high-dose methylprednisolone as a first-line therapy in adult patients with idiopathic thrombocytopenic purpura.

Alpdogan O, Budak-Alpdogan T, Ratip S, Firatli-Tuglular T, Tanriverdi S, Karti S, Bayik M, Akoglu T.

Source‎: Br J Haematol 1998;103(4):1061-3.

Indexed‎: PubMed 9886319

Intravenous anti-D treatment of immune thrombocytopenic purpura: experience in 272 patients.

Scaradavou A, Woo B, Woloski BM, Cunningham-Rundles S, Ettinger LJ, Aledort LM, Bussel JB.

Source‎: Blood 1997;89(8):2689-700.

Indexed‎: PubMed 9108386

A prospective, randomized trial of high-dose intravenous immune globulin G therapy, oral prednisone therapy, and no therapy in childhood acute immune thrombocytopenic purpura.

Blanchette VS, Luke B, Andrew M, Sommerville-Nielsen S, Barnard D, de Veber B, Gent M.

Source‎: J Pediatr 1993;123(6):989-95.

Indexed‎: PubMed 8229536

How I treat immune thrombocytopenia: the choice between splenectomy or a medical therapy as a second-line treatment.

Ghanima W, Godeau B, Cines DB, Bussel JB.

Source‎: Blood 2012;120(5):960-9.

Indexed‎: PubMed 22740443

DOI‎: 10.1182/blood-2011-12-309153

The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia.

Neunert C, Lim W, Crowther M, Cohen A, Solberg L Jr, Crowther MA; American Society of Hematology.

Source‎: Blood 2011;117(16):4190-207.

Indexed‎: PubMed 21325604

DOI‎: 10.1182/blood-2010-08-302984

Romiplostim or standard of care in patients with immune thrombocytopenia.

Kuter DJ, Rummel M, Boccia R, Macik BG, Pabinger I, Selleslag D, Rodeghiero F, Chong BH, Wang X, Berger DP.

Source‎: N Engl J Med 2010;363(20):1889-99.

Indexed‎: PubMed 21067381

DOI‎: 10.1056/NEJMoa1002625

International consensus report on the investigation and management of primary immune thrombocytopenia.

Provan D, Stasi R, Newland AC, Blanchette VS, Bolton-Maggs P, Bussel JB, Chong BH, Cines DB, Gernsheimer TB, Godeau B, Grainger J, Greer I, Hunt BJ, Imbach PA, Lyons G, McMillan R, Rodeghiero F, Sanz MA, Tarantino M, Watson S, Young J, Kuter DJ.

Source‎: Blood 2010;115(2):168-86.

Indexed‎: PubMed 19846889

DOI‎: 10.1182/blood-2009-06-225565

Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura.

Arnold DM, Dentali F, Crowther MA, Meyer RM, Cook RJ, Sigouin C, Fraser GA, Lim W, Kelton JG.

Source‎: Ann Intern Med 2007;146(1):25-33.

Indexed‎: PubMed 17200219

Therapy with high-dose dexamethasone (HD-DXM) in previously untreated patients affected by idiopathic thrombocytopenic purpura: a GIMEMA experience.

Mazzucconi MG, Fazi P, Bernasconi S, De Rossi G, Leone G, Gugliotta L, Vianelli N, Avvisati G, Rodeghiero F, Amendola A, Baronci C, Carbone C, Quattrin S, Fioritoni G, D'Alfonso G, Mandelli F; Gruppo Italiano Malattie EMatologiche dell'Adulto (GIMEMA) Thrombocytopenia Working Party.

Source‎: Blood 2007;109(4):1401-7.

Indexed‎: PubMed 17077333

High-dose dexamethasone as a first- and second-line treatment of idiopathic thrombocytopenic purpura in adults.

Borst F, Keuning JJ, van Hulsteijn H, Sinnige H, Vreugdenhil G.

Source‎: Ann Hematol 2004;83(12):764-8.

Indexed‎: PubMed 15309522

Initial treatment of immune thrombocytopenic purpura with high-dose dexamethasone.

Cheng Y, Wong RS, Soo YO, Chui CH, Lau FY, Chan NP, Wong WS, Cheng G.

Source‎: N Engl J Med 2003;349(9):831-6.

Indexed‎: PubMed 12944568

Guidelines for the investigation and management of idiopathic thrombocytopenic purpura in adults, children and in pregnancy.

British Committee for Standards in Haematology General Haematology Task Force.

Source‎: Br J Haematol 2003;120(4):574-96.

Indexed‎: PubMed 12588344

The medical section of is designed as an informational resource primarily for use by clinicians and other health-care professionals. It provides neither medical advice nor treatment recommendations and does not substitute for an appropriately qualified health-care provider. The clinical literature cited is not published by Jehovah’s Witnesses, but it outlines transfusion-alternative strategies that might be considered. It is the responsibility of each qualified health-care provider to maintain awareness of new information, discuss options for care, and assist patients in making choices in accord with their medical condition, wishes, values, and beliefs. Not all listed strategies are appropriate or acceptable to all patients.

Patients: Always seek the advice of your doctor or other qualified health-care provider regarding medical conditions or treatments. Check with a doctor if you suspect you are ill.

The use of this website is governed by its terms of use.